Efficacy and safety of inetetamab plus pertuzumab and nab-paclitaxel as neoadjuvant therapy for HER2+ breast cancer: A single-arm multicenter phase II clinical trial
机构:[1]Department of Breast Surgery, Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China[2]Department of Breast Surgery, The Affiliated Tumor Hospital of Guizhou Medical University, Guiyang, China[3]The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China[4]Department of Breast Surgery, Deyang People’s Hospital, Deyang, Sichuan, China[5]Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China[6]Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China[7]Department of Breast and Thyroid Surgery, Suining Central Hospital, Suining, Sichuan, China[8]Department of Palliative Care, Anyang Tumor Hospital, The Fourth Affiliated Hospital of Henan University of Science and Technology, Anyang, Henan, China[9]The Breast Cancer Center, Chongqing University Cancer Hospital, Chongqing, China[10]Department of Breast Surgery, Nanyang Central Hospital, Nanyang, Henan, China[11]Department of Breast Surgery, Zhengzhou University Affiliated Oncology Hospital, Henan Provincial Cancer Hospital, Zhengzhou City, Henan, China河南省肿瘤医院[12]Department of Breast Surgery, First Hospital of Jilin University, Changchun, Jilin, China[13]Department of Breast Surgery, Sichuan Cancer Hospital, Chengdu, Sichuan, China外科中心乳腺外科中心四川省肿瘤医院[14]Department of Thyroid and Breast Surgery, The First Affiliated Hospital of University of Science and Technology of China Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China[15]The First Affiliated Hospital of Wannan Medical College, WuHu, JiangXi, China[16]Department of Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China
第一作者机构:[1]Department of Breast Surgery, Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Zuo Wen-Jia,Ma Lin-Xiao-Xi,Wang Zhi-Hong,et al.Efficacy and safety of inetetamab plus pertuzumab and nab-paclitaxel as neoadjuvant therapy for HER2+ breast cancer: A single-arm multicenter phase II clinical trial[J].Cancer Letters.2025,627:217785.doi:10.1016/j.canlet.2025.217785.
APA:
Zuo Wen-Jia,Ma Lin-Xiao-Xi,Wang Zhi-Hong,Cao Xu-Chen,Jia Xin-Jian...&Shao Zhi-Ming.(2025).Efficacy and safety of inetetamab plus pertuzumab and nab-paclitaxel as neoadjuvant therapy for HER2+ breast cancer: A single-arm multicenter phase II clinical trial.Cancer Letters,627,
MLA:
Zuo Wen-Jia,et al."Efficacy and safety of inetetamab plus pertuzumab and nab-paclitaxel as neoadjuvant therapy for HER2+ breast cancer: A single-arm multicenter phase II clinical trial".Cancer Letters 627.(2025):217785